Kannabinoidy w leczeniu stwardnienia rozsianego Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2017
Słowa kluczowe:
stwardnienie rozsiane, kannabinoidy
##plugins.themes.bootstrap3.article.main##
Abstrakt
Od kilkunastu lat trwają badania nad określeniem medycznego zastosowania kannabinoidów. Obecnie są one zarejestrowane m.in. w zmniejszaniu nasilenia spastyczności w przebiegu stwardnienia rozsianego (nabiksimol będący mieszaniną tetrahydrokannabinolu i kannabidiolu). Inne wskazania obejmują leczenie bólu nowotworowego (szczególnie neuropatycznego) u pacjentów z opornością na opioidy (dronabinol, nabilon, nabiksimol), a także zespołu wyniszczenia w przebiegu AIDS (dronabinol) i łagodzenie nudności i wymiotów wywołanych przez chemioterapię (dronabinol).
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. MS society group: Spasticity, mobility problems and multiple sclerosis [online].
2. Chou R., Peterson K., Helfand M.: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J. Pain Symptom. Manage. 2004; 28(2): 140-175.
3. Novotna A., Mares J., Ratcliffe S. et al.: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 2011; 18(9): 1122-1131.
4. Członkowska A., Mirowska-Guzel D.: Choroby wewnętrzne. Stan wiedzy na rok 2010. Rozdział IX: Wybrane choroby układu nerwowego. Medycyna Praktyczna, Kraków 2010: 1971.
5. Fox P., Bain P.G., Glickman S. et al.: The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62(7): 1105-1109.
6. NICE. Spasticity in under 19s: management [online].
7. Wells D.L., Ott C.A.: The “new” marijuana. Ann. Pharmacother. 2011; 45: 414-417.
8. Ashton J.C.: Synthetic cannabinoids as drugs of abuse. Curr. Drug Abuse Rev. 2012; 5: 158-168.
9. Hoyte C.O., Jacob J., Monte A.A. et al.: A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann. Emerg. Med. 2012; 60: 435-438.
10. Kannabinoidy. W: Rang H.P., Dale M.M., Ritter J.M. (red.): Farmakologia. Elsevier Urban & Partner, Wrocław 2014: 226-231.
11. Osei-Hyiaman D., Harvey-White J., Bátkai S. et al.: The role of the endocannabinoid system in the control of energy homeostasis. Int. J. Obes. (Lond.) 2006; 30(supl. 1): 33-38.
12. Begg M., Pacher P., Bátkai S. et al.: Evidence for novel cannabinoid receptors. Pharmacol. Ther. 2005; 106(2): 133-145.
13. Abadinsky H.: Drugs: An Introduction. Wyd. 5. 2004: 62-77; 160-166.
14. Pertwee R.G.: The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. 2006; 30: 13-18.
15. Hill K.P.: Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA 2015; 313: 2474-2483.
16. Ablin J., Ste-Marie P.A., Schafer M. et al.: Medical use of cannabis products. Lessons to be learned from Israel and Canada. Schmerz 2016; 30: 3-13.
17. Koppel B.S., Brust J.C., Fife T. et al.: Systematic review efficacy and safety of medical marijuana in selected neurologic disorders. Neurology 2014; 82: 1556-1563.
18. Lohr L.: Chemotherapy-induced nausea and vomiting. Cancer J. 2008; 14(2): 85-93.
19. AOTM. Sativex - stwardnienie rozsiane [online].
20. EMA. Sativex [online].
21. Talan J.: Cannabidiol research of first hope for seizure disorders. Neurology Today 2017; 17(2): 1-10.
22. Zajicek J.P., Hobart J.C., Slade A. et al.; MUSEC Research Group: Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J. Neurol. Neurosurg. Psychiatry 2012; 83(11): 1125-1132.
23. Zajicek J., Fox P., Sanders H. et al.; UK MS Research Group: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517-1526.
24. Zajicek J., Ball S., Wright D. et al.; CUPID investigator group: Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013; 12(9): 857-865.
25. Rog D.J., Nurmikko T.J., Friede T. et al.: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812-819.
26. Svendsen K.B., Jensen T.S., Bach F.W.: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460): 253-258.
27. Whiting P.F., Wolff R.F., Deshpande S. et al.: Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA 2015; 313: 2456-2473.
28. Farrar J.T., Troxel A.B., Stott C. et al.: Validity, Reliability, and Clinical Importance of Change in a 0–10 Numeric Rating Scale Measure of Spasticity: a Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. Clin. Ther. 2008; 30(5): 974-985.
29. Anwar K., Barnes M.P.: A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. NeuroRehabilitation 2009; 24(4): 333-340.
30. Hawker G.A., Mian S., Kendzerska T. et al.: Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. (Hoboken) 2011; 63(supl. 11): S240-S252.
31. Wade D.T., Makela P.M., House H. et al.: Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 2006; 12(5): 639-645.
32. Nie ma leczniczej marihuany. Medexpress [online].
2. Chou R., Peterson K., Helfand M.: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J. Pain Symptom. Manage. 2004; 28(2): 140-175.
3. Novotna A., Mares J., Ratcliffe S. et al.: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 2011; 18(9): 1122-1131.
4. Członkowska A., Mirowska-Guzel D.: Choroby wewnętrzne. Stan wiedzy na rok 2010. Rozdział IX: Wybrane choroby układu nerwowego. Medycyna Praktyczna, Kraków 2010: 1971.
5. Fox P., Bain P.G., Glickman S. et al.: The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62(7): 1105-1109.
6. NICE. Spasticity in under 19s: management [online].
7. Wells D.L., Ott C.A.: The “new” marijuana. Ann. Pharmacother. 2011; 45: 414-417.
8. Ashton J.C.: Synthetic cannabinoids as drugs of abuse. Curr. Drug Abuse Rev. 2012; 5: 158-168.
9. Hoyte C.O., Jacob J., Monte A.A. et al.: A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann. Emerg. Med. 2012; 60: 435-438.
10. Kannabinoidy. W: Rang H.P., Dale M.M., Ritter J.M. (red.): Farmakologia. Elsevier Urban & Partner, Wrocław 2014: 226-231.
11. Osei-Hyiaman D., Harvey-White J., Bátkai S. et al.: The role of the endocannabinoid system in the control of energy homeostasis. Int. J. Obes. (Lond.) 2006; 30(supl. 1): 33-38.
12. Begg M., Pacher P., Bátkai S. et al.: Evidence for novel cannabinoid receptors. Pharmacol. Ther. 2005; 106(2): 133-145.
13. Abadinsky H.: Drugs: An Introduction. Wyd. 5. 2004: 62-77; 160-166.
14. Pertwee R.G.: The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. 2006; 30: 13-18.
15. Hill K.P.: Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA 2015; 313: 2474-2483.
16. Ablin J., Ste-Marie P.A., Schafer M. et al.: Medical use of cannabis products. Lessons to be learned from Israel and Canada. Schmerz 2016; 30: 3-13.
17. Koppel B.S., Brust J.C., Fife T. et al.: Systematic review efficacy and safety of medical marijuana in selected neurologic disorders. Neurology 2014; 82: 1556-1563.
18. Lohr L.: Chemotherapy-induced nausea and vomiting. Cancer J. 2008; 14(2): 85-93.
19. AOTM. Sativex - stwardnienie rozsiane [online].
20. EMA. Sativex [online].
21. Talan J.: Cannabidiol research of first hope for seizure disorders. Neurology Today 2017; 17(2): 1-10.
22. Zajicek J.P., Hobart J.C., Slade A. et al.; MUSEC Research Group: Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J. Neurol. Neurosurg. Psychiatry 2012; 83(11): 1125-1132.
23. Zajicek J., Fox P., Sanders H. et al.; UK MS Research Group: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517-1526.
24. Zajicek J., Ball S., Wright D. et al.; CUPID investigator group: Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013; 12(9): 857-865.
25. Rog D.J., Nurmikko T.J., Friede T. et al.: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812-819.
26. Svendsen K.B., Jensen T.S., Bach F.W.: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460): 253-258.
27. Whiting P.F., Wolff R.F., Deshpande S. et al.: Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA 2015; 313: 2456-2473.
28. Farrar J.T., Troxel A.B., Stott C. et al.: Validity, Reliability, and Clinical Importance of Change in a 0–10 Numeric Rating Scale Measure of Spasticity: a Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. Clin. Ther. 2008; 30(5): 974-985.
29. Anwar K., Barnes M.P.: A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. NeuroRehabilitation 2009; 24(4): 333-340.
30. Hawker G.A., Mian S., Kendzerska T. et al.: Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. (Hoboken) 2011; 63(supl. 11): S240-S252.
31. Wade D.T., Makela P.M., House H. et al.: Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 2006; 12(5): 639-645.
32. Nie ma leczniczej marihuany. Medexpress [online].